Waters Corporation — Cyborg Score 6/10

Solid
Analytical Instrumentation & Life Sciences Tools

Strategic Profile

Waters' analytical instruments remain the gold standard in several applications, especially LC-MS for biopharmaceutical firms, where regulations preserve consistent recurring sales for many years. In early 2026, Waters completed a merger with BD's life science and diagnostics business, substantially expanding its product portfolio beyond its traditional analytical instrumentation focus.

Cyborg Score Rationale

Waters reported 2025 revenue of $3.17 billion, an increase of 6.99% compared to the previous year. The company faces integration challenges from the BD acquisition but maintains strong market positioning in core analytical instruments. Recent guidance disappointment suggests near-term headwinds but long-term growth potential remains supported by life sciences demand.

Top Insights

  • BD Biosciences & Diagnostics merger closed February 9, 2026, representing transformational deal to expand beyond analytical instrumentation into diagnostics and life science tools
  • Strong biopharmaceutical customer concentration (58% of 2024 sales) provides recurring revenue base from regulated chromatography and mass spectrometry instruments
  • FY2025 revenue growth of 7% driven by biotech client demand but guidance revisions indicate slower-than-expected acquired BD asset performance
  • Integration risks and execution challenges from major acquisition could impact margins and synergy realization timeline

Named Competitors

  • Agilent Technologies — Leading analytical instrumentation and life sciences solutions
  • Shimadzu — Global manufacturer of analytical and measuring instruments
  • Bruker — High-performance scientific instruments and solutions
  • Thermo Fisher Scientific — Diversified life sciences and laboratory services company

Recent Developments

  • (February 2026) Completed merger with BD's Biosciences and Diagnostics business; shares declined 12% on lower guidance for acquired assets
  • (November 2025) Announced appointment of Udit Batra as President and CEO
  • (August 2025) Raised annual profit forecast citing improved biotech demand for drug development tools

Open the full interactive Waters Corporation report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →